United States
King & Spalding has now hired 15 partners from Winston Taylor and legacy firm Winston & Strawn in offices spanning Texas, San Francisco, and Chicago
Firm says its work with a biotech client could signal a sea change in how - and when - law firms enter the drug development process
Evan Lazerowitz, attorney in Robinson + Cole’s bankruptcy and reorganisation group, offers key takeaways for IP interested parties in bankruptcy and insolvency proceedings
With drug prices a hot topic in the US, courts are seemingly more reluctant to prevent the entry of generics to the market
Sponsored
Sponsored
-
Sponsored by CASMatt Garver and Peter Mattei of CAS discuss why companies should develop patent monitoring programmes -
Sponsored by Shiga International Patent OfficeMasato Iida of Shiga International Patent Office calls for greater clarity in the Japanese patent linkage system in comparing it with US and Chinese practice
-
Sponsored by PurpleVine IPJoin Ude Lu, the chief IP counsel (US) of Purplevine IP, Helen Zhang, the litigation manager of Purplevine IP in Beijing, and Penny Sun, the brand protection manager of ABRO Industry, as they discuss evidence collection for patent enforcement in China and the US virtually with Managing IP on November 9 at 10am (US ET) / 3pm (UK) / 11pm (China)
-
Sponsored by CASPeter Blasi, Global Strategic Account Manager for the CAS Ionic Affinity Program, talks to Managing IP about prior art patent searches, sharing his advice on maximising both thoroughness and efficiency
-
Sponsored by CASCAS explains how intellectual property (IP) is becoming increasingly central to companies, particularly to research and development (R&D) teams, and highlights five key findings from a survey of senior business leaders
-
Sponsored by CASCAS explains the five high-risk areas of IP for R&D organisations and identifies how companies can protect their innovations and safeguard their growth potential
